Seek Returns

CRL vs. PCVX: Charles River Laboratories vs. Vaxcyte Stock Comparison

How do Charles River Laboratories (CRL) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Charles River Laboratories (CRL) and Vaxcyte (PCVX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while PCVX is classified in Biotechnology.

Charles River Laboratories (CRL) has more than two decades of public-market history since June 23, 2000, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
Profile ItemCRLPCVX
NameCharles River Laboratories International, Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization16.17 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJune 23, 2000June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

CRL
PCVX
GSPC
Loading price history…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Charles River Laboratories (CRL) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Charles River Laboratories (CRL) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
Total Return (1Y)110.83%59.00%
Total Return (3Y, Annualized)27.87%11.29%
Total Return (5Y, Annualized)-1.57%21.60%

Risk Profile

Drawdown History

CRL
PCVX
GSPC
Loading price history…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Charles River Laboratories (CRL) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
Volatility (1Y, Annualized)47.81%56.01%
Beta (5Y)1.331.26
Max Drawdown (5Y)-74.73%-76.22%
Avg. Volume (3M)1.05M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
CRL and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
Sharpe Ratio (1Y)2.230.98
Sortino Ratio (1Y)3.581.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.27%

Max
109.18%
Q3
6.23%
CRL
1.27%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Charles River Laboratories (CRL) at 1.01% and Vaxcyte (PCVX) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01%

Max
18.05%
Q3
4.78%
CRL
1.01%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Charles River Laboratories (CRL) at 23.42% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.42%

Max
83.12%
CRL
23.42%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
ROE (TTM)1.27%-42.68%
ROA (TTM)4.74%-24.98%
Net Margin (TTM)1.01%0.00%
Operating Margin (TTM)23.42%0.00%
Gross Margin (TTM)35.10%0.00%

Growth

Revenue Growth

Only one side can be read here: Charles River Laboratories (CRL) reports revenue growth of -0.85%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
Revenue Growth (YoY)-0.85%--
Revenue Growth (3Y CAGR)0.33%--
EPS Growth (YoY)-1,555.00%--
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.41

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
CRL
1.41
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
1.42
CRL
0.87
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
Current Ratio (MRQ)1.414.56
Debt / Equity (MRQ)0.870.09
Net Debt / EBITDA2.92--

Dividends

Dividend Yield (TTM)

Neither Charles River Laboratories (CRL) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

CRL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Charles River Laboratories (CRL) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

CRL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

366.87

CRL
366.87
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; CRL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Charles River Laboratories (CRL), whose P/S ratio of 4.07 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.07

Max
58.18
Q3
25.77
Median
7.30
CRL
4.07
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; CRL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Vaxcyte (PCVX) at 3.83 are valued close to their industries’ norm against book — neither stands out from peers.

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.01

Max
13.53
Q3
6.54
CRL
5.01
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Charles River Laboratories (CRL) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Charles River Laboratories (CRL) and Vaxcyte (PCVX)
MetricCRLPCVX
P/E Ratio (TTM)366.87--
P/S Ratio (TTM)4.07--
P/B Ratio (MRQ)5.013.83
Free Cash Flow Yield (TTM)2.74%-5.24%